Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.
Study Type
OBSERVATIONAL
Enrollment
335
Hvidovre University Hospital
Hvidovre, Denmark
RECRUITINGIdentification and validation of a diagnostic classifier enabling discrimination of chronic liver diseases.
OMICS based analyses on plasma and liver tissue
Time frame: 10 years
To identify any metabolic disturbances within chronic liver diseases
Collection of plasma during an oral glucose tolerance test measuring pancreatic and gut hormones
Time frame: Plasma obtained at time point 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.